Marshall Wace, LLP Eli Lilly & CO Call Options Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $1.78 Million - $2.21 Million	2,300 Added 766.67%	2,600 $2.3 Million
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $289,948 - $363,616	-400 Reduced 57.14%	300 $271,000
Q1 2024 May 15, 2024	SELL	$592.2 - $792.28 $118,440 - $158,456	-200 Reduced 22.22%	700 $544,000
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $3.78 Million - $4.46 Million	-7,200 Reduced 88.89%	900 $524,000
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $2.43 Million - $3.36 Million	5,600 Added 224.0%	8,100 $4.35 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $876,850 - $1.17 Million	2,500 New	2,500 $1.17 Million
Q2 2021 Aug 13, 2021	BUY	$180.55 - $233.54 $343,045 - $443,726	1,900 New	1,900 $436,000

4,003

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $709B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.